Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 7/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317564 | 0.89 | C3AR1 (0.42) | C3AR1FOLH1FURINCTDSP1NOD1 | |
| SCHEMBL24191073 | 0.89 | C3AR1 (0.42) | C3AR1FURINCTDSP1NOD1PRSS1 | |
| SCHEMBL18688864 | 0.89 | GNPAT (0.45) | C3AR1FOLH1FURINSIRT5GNPAT | |
| SCHEMBL28574926 | 0.89 | GNPAT (0.45) | C3AR1FOLH1FURINSIRT5GNPAT | |
| SCHEMBL31319761 | 0.88 | C3AR1 (0.41) | C3AR1FURINCTDSP1NOD1PRSS1 | |
| SCHEMBL30413729 | 0.87 | C3AR1 (0.52) | C3AR1FOLH1GNPATCTDSP1NOD1 | |
| SCHEMBL2369351 | 0.87 | C3AR1 (0.39) | C3AR1FOLH1FURINGNPATCTDSP1 | |
| SCHEMBL29385639 | 0.86 | C3AR1 (0.45) | C3AR1FOLH1FURINCTDSP1NOD1 | |
| SCHEMBL31666024 | 0.86 | NOD1 (0.40) | C3AR1FURINCTDSP1NOD1PRSS1 | |
| SCHEMBL30881175 | 0.85 | NOD1 (0.45) | C3AR1FOLH1FURINNOD1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213715-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORP (US) | 2025-07-03 | — | — | US | claimed |
| WO-2022082066-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORPORATION (US) | 2022-04-21 | — | — | WO | claimed |
| US-20250213715-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORP (US) | 2025-07-03 | — | — | US | disclosed |
| CN-116782955-A | anti-CSPG 4 binders, conjugates thereof, and methods of use thereof | 艾迪健公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022082066-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213715-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | CD2BP2, SDCBP, PA2G4 | C3AR1 1014/4885FOLH1 236/4885FURIN 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.